At the news
? NEUTRALIMPACT 4/10 DEFA14A filed Apr 24, 2026 at 06:25 ET
Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and ratify the appointment of Ernst & Young as auditors. This follows a recent board reclassification to balance director classes, indicating ongoing governance adjustments.
- Proxy statement seeks approval for three Class II director nominees: Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.
- Proposal to ratify Ernst & Young as independent auditors for 2026.
- Follows a recent board reclassification of Steven D. Harr from Class I to Class III to balance board classes.
- No other business is expected at the annual meeting.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access